Chronic Lymphocytic Leukemia: Individualizing Treatment Approach

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Chronic lymphocytic leukemia (CLL) treatment landscape is evolving.
• New therapeutic agents are available for upfront and relapsed/refractory settings.

Purpose of the Study:

• Discuss the role of prognostic markers in CLL treatment selection.
• Review first-line therapy options and novel agents for relapsed/refractory CLL.
• Highlight advancements towards achieving minimal residual disease negativity and durable remissions.

Main Methods:

• Discussion of the CLL-International Prognostic Index for risk stratification.
• Review of optimal first-line therapy options.
• Presentation of updated clinical trial data on novel agents.

Main Results:

• Established and emerging prognostic markers aid treatment selection.
• Novel agents show promise in the relapsed or refractory setting.
• Focus on achieving high rates of minimal residual disease negativity.

Conclusions:

• Optimal use of new CLL therapies is still being defined.
• Prognostic markers are crucial for personalized treatment strategies.
• Future treatments aim for durable remissions by replacing chronic therapy with effective combinations.